FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileCambium Bio Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Discussion
CMB.AX
Cambium Bio Limited Stock AnalysisComprehensive stock analysis for Cambium Bio Limited (CMB.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisCMB.AX
CMB.AX
Cambium Bio Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Discussion
CMB.AX
  1. Home
  2. Stocks
  3. Cambium Bio Limited

Cambium Bio Limited

🇦🇺CMB.AX•ASX

Cambium Bio Limited

🇦🇺CMB.AX•ASX

Your view on CMB.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Cambium Bio Limited

Industry
Biotechnology
Sector
Healthcare
CEO
Karolis Rosickas
Headquarters
Unit 2.06/31 Lexington Dr, Bella Vista, NSW, AU
Industry
Biotechnology
Sector
Healthcare
CEO
Karolis Rosickas
Headquarters
Unit 2.06/31 Lexington Dr, Bella Vista, NSW, AU
Description

Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease.

The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Cambium Bio Limited. Starting points for Cambium Bio Limited: EPS -AUD 0.24, beta -0.13 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Cambium Bio Limited. Cambium Bio Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Cambium Bio Limited. Trailing twelve-month EPS for Cambium Bio Limited stands at -AUD 0.24. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026
More →

Earnings per share estimates

Per shareThis yearYear to Jun 2027Next yearYear to Jun 2028
Average estimate−AUD 0.00−AUD 0.00
Lowest estimate−AUD 0.00−AUD 0.00
Highest estimate−AUD 0.00−AUD 0.00
Number of analysts11
A year ago−AUD 0.171—
Growth vs a year ago——

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis yearYear to Jun 2027Next yearYear to Jun 2028
Average estimateAUD 795244.00AUD 2.19M
Lowest estimateAUD 795244.00AUD 2.19M
Highest estimateAUD 795244.00AUD 2.19M
Number of analysts11
A year agoAUD 641638.00—
Growth vs a year ago+23.9%—

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Cambium Bio Limited. Cambium Bio Limited has reported as a listed company since 2016. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold CMB.AX19 companies
Compare CMB.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
CAZ.AXCazaly Resources LimitedBasic MaterialsIndustrial Materials—
CHM.AXChimeric Therapeutics LimitedHealthcareBiotechnology—
CPN.AXCaspin Resources LimitedBasic MaterialsIndustrial Materials—
CVR.AXCavalier Resources LimitedBasic MaterialsGold—
IMM.AXImmutep LimitedHealthcareBiotechnology—
KURAKura Oncology, Inc.HealthcareBiotechnology$674.4M
OLMAOlema Pharmaceuticals, Inc.HealthcareBiotechnology$618.5M
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PTX.AXPrescient Therapeutics LimitedHealthcareASX—
PULMPulmatrix, Inc.HealthcareNASDAQ$4.9M
PVCTProvectus Biopharmaceuticals, Inc.HealthcareOTC$18.7M
PVLAPalvella Therapeutics, Inc.HealthcareNASDAQ$2.1B
PXMDPaxMedica, Inc. Common StockHealthcareOTC$37,879
PXXLFPoxel S.A.HealthcareOTC$13.4M
PYC.AXPYC Therapeutics LimitedHealthcareASX—
OBXObsidian Therapeutics Inc.HealthcareNASDAQ$12.7M
OCC.AXOrthocell LimitedHealthcareASX—
OCEAOcean Biomedical, Inc.HealthcarePNK$1.2M
OCGNOcugen, Inc.HealthcareNASDAQ$250.8M
OCSOculis Holding AGHealthcareNASDAQ$456.2M
Open Comparable Analysis
Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Cambium Bio Limited.

CMB.AX AnalysisFair
Past
2
Growth
2
Health
5
Profit
1
Value
1